Author

A. Makda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Assay:imaging· 1 Assay:metabolomics· 1

Frequent Co-Authors

N. O. Carragher· 3 shared A. F. Munro· 2 shared J. R. O'Neill· 2 shared R. E. Hughes· 2 shared T. Hupp· 2 shared A. Byron· 1 shared A. Garcia-Munoz· 1 shared A. von Kriegsheim· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

N. O. Carragher

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

High-content profiling reveals a unified model of copper ionophore dependent cell death in oesophageal adenocarcinoma

R. E. Hughes, R. J. Elliott, X. Li, A. F. Munro, A. Makda, R. N. Carter, N. M. Morton, K. Fujihara, N. J. Clemons, R. Fitzgerald, J. R. O'Neill, T. Hupp, N. O. Carragher

This study identifies a unified mechanism of copper ionophore-induced cell death in oesophageal adenocarcinoma using high-content profiling and omic analyses.

bioRxiv · Oct 5, 2021 · PreprintCancer Biology

High Content Phenotypic Profiling in Oesophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery

R. E. Hughes, R. J. R. Elliott, A. F. Munro, A. Makda, J. R. O'Neill, T. Hupp, N. O. Carragher

This study uses high-content phenotypic profiling to identify drug classes and novel compounds with selective activity against oesophageal adenocarcinoma cell lines.

bioRxiv · Jan 20, 2020Cancer Biology

A Synergistic Anti-Cancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High Content Phenotypic Screen

J. C. Dawson, B. Serrels, A. Byron, M. Muir, A. Makda, A. Garcia-Munoz, A. von Kriegsheim, N. O. Carragher, M. C. Frame

The paper identifies a synergistic combination of FAK and HDAC inhibitors using a chemical-genetic high-content screen, showing efficacy in cancer cell lines and in vivo.

bioRxiv · Mar 27, 2019Cancer Biology